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INTRODUCTION 
 There have been several studies on the biochemical processes related to preeclampsia, 
intrauterine growth restriction, and premature rupture of membranes that provide evidence that 
oxidative stress may be part of the pathological processes in these diseases.  Therefore 
antioxidants such as vitamin C may be preventive.(1-4)  The biochemical evidence prompted 
researchers to pursue further studies to investigate whether vitamin C use during pregnancy 
would change the incidence rate of certain obstetrical outcomes.  Often preeclampsia and 
premature rupture of membranes are indications for preterm delivery and the nutritional status of 
a woman has also been implicated in premature birth.(5)  Therefore, this review will attempt to 
answer the question: does vitamin C use during pregnancy decrease the incidence of preterm 
birth? (Preterm birth for the purpose of this review is birth before completion of the 37th week of 
gestational age) 
Burden of Suffering 
 Almost one third of all infant deaths in the United States (US) are associated with 
preterm birth.(6)  Even if a premature infant survives the first year of life, they have higher death 
rates during childhood than children born at full term.(7)  Not only is preterm birth a significant 
risk factor for infant mortality, it is also a significant cause of morbidity. It should be noted that 
most of the data available on morbidity can be confounded by the low birthweight typical of 
preterm infants.  Low birthweight can be caused by other factors besides birth at an early 
gestational age such as intrauterine growth restriction.  However, in most infants, their 
birthweight and gestational age at delivery are closely correlated.  Evidence has demonstrated 
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higher incidence rates of blindness, deafness, cerebral palsy, lower IQ, and subnormal height in 
babies born with low birthweight and low gestational age.(8) 
Epidemiology 
 According to the Centers for Disease Control and Prevention (CDC), in 2009 12.2% of 
all births in the US were pre-term.  Although this represents a decrease from the previous two 
years where the rate was 12.7% in 2007 and 12.3% in 2008, the rate remains substantially higher 
than it was in 1990 when the rate was 9.7%.  In general, the rate of preterm births has been 
increasing in the US since the 1980s with a peak occurring in 2006 at 12.8% of all births.(9)  The 
causes behind this trend are multi-factorial. One explanation for the increase in preterm birth rate 
is the increased use of artificial reproductive technology (ART) and the associated increase in 
multiple gestation pregnancies.  A multiple gestation pregnancy is an important risk factor for 
preterm birth because 50% of all twins and 90% of all triplets are born prematurely.  Multiple 
gestations as a risk factor for preterm birth is independent of the use of ART.  However, the 
increased use of ART is contributing to a rise in the incidence of multiple gestations.  For 
example: the rate of twin births increased 70% between 1980 and 2004.(10) 
 Preterm birth continues to have a large racial disparity within the US.  In the 1990s the 
rate of preterm birth for African-Americans was twice that of Caucasian Americans.  The gap 
has decreased somewhat but the decrease is more as a result of increasing rates in Caucasian 
Americans rather than a decrease for African Americans.(11)  The difference in incidence rates 
between African-Americans and Caucasians in the US has socioeconomic and genetic causes.  
Specific gene loci continue to be identified that may contribute to preterm birth but also from a 
public health perspective the socioeconomic effect is worrisome.(12)  Evidence has not shown 
that enhanced prenatal care reduces the incidence of preterm birth but it does support the benefit 
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of obtaining standard of care which is not as readily available for all socioeconomic groups.(13)  
The World Health Organization estimates an incidence rate 9.6% for preterm births worldwide 
and found increasing trends in preterm birth rate similar to the US in the United Kingdom and 
the Scandinavian countries.(14) 
Risk Factors 
 The description of preterm birth risk factors has been difficult for three reasons: One, 
most cases of preterm birth occur in women with no identifiable risk factor. Secondly, many of 
the risk factors are also associated with other obstetrical complications which themselves are 
preterm birth risk factors. Lastly, there is not an animal model useful for studying the question.  
A complete table of characteristics thought to be risk factors for preterm birth is included in 
Appendix C and some of the better defined ones pertinent to this review will be discussed here.  
As discussed above, multiple gestations and African-American race are both risk factors for 
preterm birth.  Previous history of preterm birth and second trimester abortions are also 
important risk factors for preterm birth.  One of the more recent large cohort studies involving 
>450,000 women showed after a women delivered between 32 and 36 weeks gestational age, the 
next delivery had an odds ratio of 6.12 to be preterm compared to women with a delivery after 
37 weeks.  Women with deliveries <32 weeks had even higher odds ratios of 12.0-13.1 to have a 
subsequent preterm birth.(15)  Any type of miscarriage can increase the risk of subsequent 
preterm birth but second trimester abortions have the largest affect.  Two retrospective cohort 
studies had preterm rates of 39%(16) and 33%(17) in the pregnancy following a second trimester 
abortion. 
 Preeclampsia can be an iatrogenic cause of preterm birth and is also independently a risk 
factor for future preterm births even if the later pregnancy is normotensive.  Two large cohort 
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studies followed women for at least two pregnancies.  Each showed increased risk of preterm 
birth in a pregnancy following one complicated by preeclampsia even when the second 
pregnancy was normotensive.  The amount of increased risk was dependent on the gestational 
age at delivery and at diagnosis of preeclampsia during the first pregnancy.  For all 
combinations, the rate of preterm birth was higher than for those in the cohort without 
preeclampsia in the first birth.(18, 19)  The risk of a preterm birth in women with a history of 
preeclampsia is also increased if a future pregnancy is also complicated by preeclampsia. 
 Some other risk factors for preterm birth include chronic medical diseases and smoking.  
In a Swedish cohort study involving 311,977 women, smoking was shown to be a risk factor for 
preterm birth in a dose dependent manner.  The study showed increased rates of other obstetrical 
complications also associated with preterm birth (e.g. preeclampsia) but after controlling for 
these, an independent increase in risk was also found.(20)  In a prospective observational study 
using 2,738 women in a control group, 462 women with diabetes mellitus, and 761 women with 
chronic hypertension.  Both chronic diseases showed an increase risk for preterm birth.  Women 
with diabetes had a preterm birth rate of 38%, those with hypertension-33.1%, and women in the 
control group-13.9%.(21) 
Existing Interventions 
 The data on many suggested intervention for preventing preterm labor is limited. 
Approximately 20% of preterm births in the US are secondary to iatrogenic interventions related 
to other obstetrical complications.(8)  A discussion of the prevention and treatment methods for 
each of these is beyond the scope of this review.  Some interventions directly related to 
decreasing risk factors mentioned above include smoking cessation and judicial ART use to 
reduce multiple gestations.  Other fairly straight forward interventions targeted towards specific 
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risk factors include treatment of symptomatic bacteruria, avoidance of cocaine, cervical cercalge 
for patients with cervical incompetence, proper nutrition, avoidance of occupational stress, and 
avoiding a short interpregnancy interval. 
 Two interventions that are more widely targeted at preventing preterm birth are 
supplemental progesterone and tocolytic therapy.  A systematic review of 8 RCTs and nine other 
articles found evidence for the use of progesterone to decrease the risk of preterm birth.  The 
strongest evidence was found in women with a prior history of preterm birth; however there was 
also evidence of a reduction in risk for women with a shortened cervix.(22) Tocolytic therapies 
are interventions aimed at stopping the labor process.  Therefore, any woman experiencing 
preterm labor may be given these therapies with the goal of delaying delivery.  In general, no 
therapy has been found to significantly delay the labor process and most tocolytic therapies are 
used primarily to allow the administration of steroids for 48hrs to enhance infant lung maturity 
prior to delivery.  There are many possible interventions that fall under tocolytic therapy 
including: beta-agonists, magnesium sulphate, oxytocin receptor antagonists, cox inhibitors, 
calcium channel blockers, and nitric oxide donors.  Unfortunately, the studies investigating each 
of these therapies are of varying quality and a full discussion of each is beyond the scope of this 
review.  The key point to be made about tocolytic therapy is that it is not preventive; rather it is 
an intervention during preterm labor to attempt to delay the labor for days at most.(23) 
Vitamin C for Prevention 
 According to the Institute of Medicine, a pregnant woman 19 years or older has a 
recommended dietary allowance for vitamin C of 85mg/day and for those 18 years or younger 
the recommendation is 80mg/day.  Vitamin C or ascorbic acid is water soluble nutrient with 
antioxidant properties and is a cofactor in the synthesis of camitine, collagen, and 
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neurotransmitters.(24)  The antioxidant properties of vitamin C may have significant value 
during pregnancy given the link between oxidative stress and unfavorable outcomes such as 
preeclampsia and intrauterine growth restriction.(1)(2)  Vitamin C is also involved in the 
metabolism of iron in the body and therefore may exert an additional beneficial affect during 
pregnancy by preventing anemia.(24)  Historically, vitamin C has not been taken during 
pregnancy as a stand-alone nutritional supplement; however, it is contained in many 
multivitamin formulations which are often utilized.  The increased recommended daily intake is 
based on higher metabolic demands during pregnancy and not for treatment or prevention of any 
specific pathologic process. 
In the US, around 50% of preterm births are due to preterm labor, 30% secondary to 
premature rupture of membranes, and 20% secondary to another condition (such as associated 
with preeclampsia).(8)  Relevant to preterm births due to preterm labor, a review of available 
studies found maternal nutritional status can affect gestational length.  There was an increase in 
the incidence rate of preterm birth in women with nutritional deficiencies.(5)  For preterm births 
related to premature rupture of membranes, Woods et al(3) suggested a link between vitamin C 
use and the prevention of premature rupture of membranes based on biochemical evidence. 
Myatt and Cui(1) also described histological and biochemical evidence that using vitamin C for 
its antioxidant properties may be helpful in pregnancies with intrauterine growth retardation and 
preeclampsia.  Similar data has been provided by other studies in the past as well.(2, 4) Based on 
this growing body of evidence regarding the potential benefits of antioxidants many trials were 
begun to investigate the benefits and harms of using vitamin C at higher doses than what is 
typically present in a multivitamin supplement. 
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Harms of Vitamin C Use 
 The most common side effect from increased vitamin C ingestion is diarrhea and other 
gastrointestinal disturbances which are usually associated with intakes >3grams per day.(24)  
There is a case report of a fatal cardiac arrhythmia in a patient with iron overload and taking high 
doses of vitamin C.  The case report argued there was increased oxidative stress leading to 
cardiomyopathy which caused the arrhythmia.(25)  Another case report is available describing a 
woman having false-negative stool guaiac testing. The link between the ascorbic acid and false-
negative test was backed up with in vitro evidence.  In the study, the patient was ingesting 1-2g 
of vitamin C/day and was using a guaiac test that may no longer be in use as the report is from 
1975. (26)   
Key Question Formulation 
 The key question for this review was developed to determine if vitamin C use during 
pregnancy can reduce the number of preterm births regardless of whether the decreased 
incidence is an indirect effect by decreasing other obstetrical outcomes such as preeclampsia or 
premature birth or as a direct effect through any identified or unidentified mechanism. Details on 
the inclusion and exclusion criteria for studies included in this review are discussed in the 
methods sections below.  After performing the database searches, I realized only studies on 
vitamin C alone and on vitamin C and E were found.  Also, the studies could be easily divided 
into high and low risk study populations.  Therefore the key question was answered for each 
grouping of intervention (C alone versus C and E) and risk profile (high versus low).  A high risk 
population contained at least one of the important risk factors mentioned above: history of 
preterm birth, preeclampsia, or chronic maternal medical disease.  The final key question for this 
review was: 
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• What is the evidence in randomized controlled trials performed at any time prior to this 
review for pregnant women in the US to use vitamin C prior to starting the third trimester 
as prevention of preterm birth when compared to placebo in populations similar to the 
US? 
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METHODS 
Inclusion and Exclusion Criteria 
 Studies in this review were assessed using the following criteria to determine whether 
they should be included or excluded.  The first criterion to determine the inclusion of a study 
pertains to the population of the study.  To be included, a study needed to use a study population 
consisting of pregnant women.  There were no limits on age, socioeconomic status, 
ethnicity/race, or any of factors to allow for the inclusion of all evidence available.  If the 
population differed greatly from the US population on any of these factors, it was accounted for 
as part of the external validity evaluation. 
The target of this review is to assess the effectiveness of vitamin C and therefore studies 
were only included if they used vitamin C in their intervention.  More specifically, the studies 
should have utilized a vitamin C intervention starting prior to the third trimester.  I decided 
studies should initiate the intervention prior to the third trimester to be more representative of a 
preventive therapy prior to many obstetrical outcomes being identified.  On the other hand, it 
was not required for studies to start early than the second trimester because it would be difficult 
to enroll patients this early in their pregnancy and most abortions occurs in the first trimester.  
Also, no limit was placed on the vitamin C dose level as part of my inclusion/exclusion criteria.  
Similar to above, this was done to allow the inclusion of all available evidence during the study 
assessment step of this review.  During the internal validity, an assessment regarding the dose 
level of vitamin C used is made.  Study’s that do not provide evidence that their dose would have 
a meaningful impact based on their population’s dietary patterns or used high enough doses that 
this evidence was unnecessary would be graded poor and excluded from the conclusions of this 
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review.  Studies were included if the intervention included vitamin C and up to one other 
supplement other than iron.  This was done to allow for co-administration of other antioxidant 
therapies while limiting the confounding effect of other therapies by not allowing for multi-drug 
regimens. 
Every study included in this review needed to have a control group taking a placebo.  
Requiring the studies to use a control group helps eliminate the placebo effect and enhances 
blinding.  Part of the placebo effect is a change in patient’s expectations when taking medication.  
This change in expectation can affect outcomes by changing physician-patient interactions.  For 
example, all participants are aware of the intervention due to the consent process and without a 
placebo, the control group would know they are not getting the intervention.  Therefore, 
participants in the control group may have a lower threshold for visiting the physician because 
they perceive they are ‘missing out’ on the treatment.  The second benefit of having a placebo 
controlled trial deals with blinding.  If participants are not receiving a placebo they are likely to 
know they are part of the control group and the clinician may become aware of this as well.  The 
patient or clinician’s knowledge as to whether they are part of the intervention or control arm 
may subconsciously affect the treatment plan utilized.  Therefore, all trials included in this 
review needed to be double-blinded to enhance internal validity.  The use of a placebo in the 
control arm enhances the blinding within the trial. 
Each study included in this review must provide data on the number of pre-term births, 
defined as births occurring prior to 37 weeks as one of their reported outcomes.  Studies 
published at any time were included in the review to ensure as much of the available evidence 
was included.  Studies were included only if performed in Organization for Economic Co-
operation and Development (OECD) member countries.  This limitation was used to increase the 
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generalizability of the study results to the US population.  As mentioned above, if significant 
differences in the baseline characteristics of the study population and the US population were 
reported within the study, this was taken into account as part of the external validity assessment.  
The final criterion used to define the inclusion and exclusion criteria for this review is the study 
design which needed to be a randomized control trial.  The above set of criteria is listed below in 
PICOTS format in Table 1. 
Table 1: Research Question in PICOTTSS Format 
Category Criteria 
Population Any pregnant woman 
Intervention Vitamin C alone or with up to one other supplement excluding iron.  
This excludes studies with combined supplements such as 
multivitamins 
Comparison Placebo 
Outcomes Pre-term labor 
Timing Supplementation started before the third trimester 
Time of search Entire database 
Setting OECD Countries 
Study Design Randomized controlled trials 
 
Data Sources and Searches 
 I searched PUBMED, Cochrane library, and EMBASE using the terms (“Vitamin C” OR 
“Ascorbic Acid”) AND (Pregnancy OR Pregnant).  A research librarian was consulted to help in 
developing these terms and any limitations used during the searches.  For details on the search 
strategy please see Appendix A. I also searched clinicaltrials.gov for any unpublished and 
ongoing studies relevant to this review.  I also hand searched the reference sections of the articles 
found in the above searches for any further studies relevant to this review.  These searches were 
all limited to English language and human subjects and performed with no date limits giving 
results since the inception of the relevant database. 
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Study Selection 
 Another reviewer and I analyzed the results of the above searches looking at the titles and 
abstracts to identify randomized controlled trials related to this review.  Only studies that could 
be easily excluded were eliminated at this point with the rest being retained for full text review to 
determine if they met the inclusion criteria for this review.  During the title and abstract phase of 
eliminating articles, if either reviewer felt the article should be included for full text review, it 
was.  If there was any disagreement after independent full text review, the other reviewer and I 
met to discuss the article and any concerns about its inclusion or exclusion.  If a consensus could 
not be reached after this meeting, a third reviewer was utilized. At this point all studies to be 
included in this review were identified and quality grading began.  If a study had multiple 
articles published based on its results, the study was given a single quality score and all data 
pertinent to this review was utilized. 
Study Quality Assessment – Internal Validity 
 Another reviewer and I assessed the quality of each study included in the review.  We 
used the USPSTF internal validity criteria for randomized controlled trials as the guidelines to 
assess the quality of each individual study.  This resulted in grades of good, fair, or poor for each 
study.  While grading each study’s internal validity the first consideration pertains to how 
effectively the studies setup the initial intervention and control groups.  Studies are graded based 
on how well they established concealment, maintained randomization, and if the groups 
contained equivalent distributions of possible factors that could be confounding.  Ideally each 
study would maintain double-blinding and none of the confounders would have statistically 
significant differences between each group.  Once the groups have been established the next way 
a study can enhance internal validity is dependent on how well the groups are maintained which 
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is determined by attrition, crossovers, adherence, and contamination.  In order to properly 
evaluate a study, it should report information on these rates.  However, if some of the 
information is not available in the published study, it will still be graded based on what is 
available with conservative assumptions about the missing data.(27) 
As described above, the creation and maintenance of the intervention and control groups 
are important factors in determining the internal validity of a study.  However, other factors also 
contribute.  One other factor is whether the study utilized measurements appropriate for the 
study, equal between groups, valid, and precise. For this review the outcome is a birth prior to 37 
weeks gestational age.  Therefore, each study should measure gestational age using the same 
methods between groups and report what methods were used (e.g. last menstrual period or 
ultrasound dating).  Some other important considerations for study’s being reviewed here are that 
the intervention is clearly defined and meets the inclusion criteria and the data is reported as 
intention to treat.  Another aspect of each study we used to determine internal validity was 
whether the study provided any information on the baseline intake level of the vitamin(s) 
included in their intervention.  Ideally, a study would gather information on dietary patterns and 
report the expected intake for study participants based on their normal diet.  The internal validity 
of the study would be enhanced if the dose of the intervention was higher than the baseline 
dietary intake of the participants. This interplay between the baseline dietary intake of the study 
population and intervention dose is also addressed as part of the external validity due to 
differences in dietary patterns in the US population and some of the study’s source 
population.(27)   
For all of the above aspects of our quality assessment the totality of their effect on 
internal validity was determined independently by each reviewer to determine a grade of good, 
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fair or poor.  Any discrepancies between reviewers were handled by meeting to attempt to reach 
a consensus or if necessary a third reviewer was utilized.  Studies with poor quality are those 
considered to have a ‘fatal flaw’ in their design and were excluded from the data synthesis and 
conclusions portion of this review.  Studies rated as fair, did not meet the highest standards but 
still provide useful information for this review and are used in the data synthesis and conclusion 
sections with the appropriate level of caution.(27) 
Study Quality Assessment – External Validity 
Both reviewers assessed each study to determine its external validity.  We used the 
USPSTF guidelines for external validity.  In summary, studies are rated good if they have a high 
probability (>90%) that the outcome observed in the study would also occur in US primary care 
given the same intervention.  For a fair quality rating it would need to have a moderate 
probability (50-89%) and poor would be for anything less (<50%).  Similar to the internal 
validity assessment, poor quality studies were those considered to have a ‘fatal flaw’ and were 
excluded from the data synthesis and conclusion sections.  Good and fair quality studies were 
included in these sections with the appropriate caution when utilizing the studies rated as 
fair.(27) 
Assessing the external validity of a study included in this review can be broken down into 
three broad categories: the study population, the situation of the study, and the providers in the 
study.  While assessing the studies for external validity in relation to the study population we 
tried to determine if the study population represented the patient population in the US well.  One 
key characteristic, if reported by the study, would be to assess differences in nutritional status 
prior to study initiation.  Also, we can assess the demographic information of the study 
participants relative to the US population.  Another important aspect is whether the study’s 
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population presented with more or less risk factors than a comparable group in the US.  The 
results of this review were divided between studies with high and low risk study populations 
based on their inclusion and exclusion criteria.  For this review, the number of possible risk 
factors is high and therefore smaller studies may have some variability on individual co-
morbidities.  Therefore, a goal of our assessment was to attempt to quantify whether it was a 
systematic problem with the study’s population related to recruitment/study design or if it was 
merely an expected result due to random occurrences in a small study population.(27) 
Another study design characteristic relevant to the study population is the recruitment 
method used.  Therefore we assessed this in our external validity grading.  Some of the data we 
looked at included: rate of refusal by those approached about the study, source population for 
recruitment, and intensity of recruitment tactics.  These factors may affect the adherence to 
treatment of the study population.  When analyzing a study’s protocol regarding adherence, we 
were looking for any measures that might increase the adherence to the intervention to a level 
that is not representative of the general patient population for this review.(27) 
The other two broad categories assessed while grading studies for their external validity 
were the situation within which the study was performed and the providers included in the study.  
The situation of the study pertains to the healthcare system, country, study locations, and cost of 
the intervention and whether these factors are similar to what might be expected when 
introducing the intervention to the all pregnant women.  The external validity of a study may be 
decreased if the providers in the study have a skill set or knowledge set that differs from the 
practitioner expected to be providing the intervention to the regular patient population.  For the 
intervention under review here, this should not be an issue for many studies.  However, pertinent 
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to the outcome, some providers may be more or less capable in their attempts to delay delivery if 
necessary and this will be considered during the assessment.(27) 
Data Collection 
 Both reviewers abstracted data from each study to be used in the quality assessments 
mentioned above and also for use in analyzing the outcomes results of the studies in developing 
the conclusions of this review.  The data was placed in an Excel file for reference.  Below is an 
example list of the type of data compiled for each study: 
• Study Population- Demographic Data, Size, Dropout Rates 
• Intervention- Dosage, Time Length, Information on Adherence 
• Outcome- Risk Ratios with confidence intervals if reported, otherwise they were 
calculated 
• Risk Factors Reported as Statistically Different Between Groups 
• Risk Factors Reported as Statistically Similar Between Groups 
• Funding Source 
Data Synthesis 
 Using the quality rating given to each individual study, a qualitative comparison was 
performed for the outcome measure: pre-term birth.  The data will be reported for studies 
deemed to have overall quality of fair or good.  Results will also be divided into groups of 
studies based on the risk level of the study population and intervention used.  No computational 
combination of results will be derived for this review.  However, a discussion of the synthesis of 
evidence from the studies identified will be included.  For this review’s discussion, studies 
considered to be of good quality will be given more influence upon the final conclusion than 
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those with fair quality ratings.  For this review, as above, we will be utilizing methods similar to 
USPSTF when analyzing preventive services.  Evidence for the key question, based on 
intervention and risk grouped, will be graded as convincing, adequate, or inadequate.  The 
USPSTF uses the following six questions to guide critical appraisal.  For individual studies 
questions 1-3 and 6 are assessed and help determine the internal and external validity grades.  
When synthesizing the evidence across studies, all questions are utilized to determine the grade 
for the level of evidence to answer the key question.  The level of evidence may also be referred 
to as certainty or strength of evidence. 
1. Do the studies have the appropriate research design to answer the key question(s)? 
2. To what extent are the existing studies of high quality? (i.e., what is the internal validity?) 
3. To what extent are the results of the studies generalizable to the general US primary care 
population and situation? (i.e., what is the external validity?) 
4. How many studies have been conducted that address the key question(s)? How large are 
the studies? (i.e., what is the precision of the evidence?) 
5. How consistent are the results of the studies? 
6. Are there additional factors that assist us in drawing conclusions (e.g., presence or 
absence of dose-response effects; fit within a biologic model)?(27) 
Assessment of Bias Across Studies 
 One of the most common concerns for bias when determining conclusions from the 
synthesis of multiple studies is the risk of publication bias.  In an attempt to find information on 
unpublished studies I searched clinicaltrials.gov.  I also searched PubMed, EMBASE, and Web 
of Science using the search terms detailed above with limits activated to find conference 
proceedings and meeting abstracts in order to identify studies presented in these settings that may 
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not have been published in a journal due to the lack of significant findings.  I also conducted a 
brief expert interview with a local expert in an attempt to identify if they knew of any studies 
performed without any data being published. 
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RESULTS 
Search Results 
 I searched the databases on February 28, 2012 using the strategy described above and 
found the following number of records in each database: PUBMED-121, Cochrane-103, and 
EMBASE-105.  I then removed any duplicate records and studies on non-human subjects to 
obtain 230 articles for title and abstract review.  The second reviewer and I analyzed the title and 
abstracts for these studies and at this point we excluded studies based on study design, study 
population, or lack of outcomes or intervention related to this review’s question.  This resulted in 
32 studies that went on for full text review. From these studies, I was unable to identify any 
additional studies from hand searches of their citations.  After full text review, we excluded 23 
studies based on the inclusion and exclusion criteria detailed in the methods section and 9 
remained to be included in the review for a full critique and assessment. Figure 1 below shows 
this progression as a flow chart.  It should be noted here that only studies assessing either vitamin 
C alone or a combination of vitamin C and E were identified and included in the rest of this 
review. 
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Study Characteristics 
 Table 2 below gives information on each individual study included in the quality 
assessment.  In summary, the studies included 18,262 women when the intervention was vitamin 
C and E with 9,151 in their control groups and 9,111 women in the intervention groups.  For 
studies where the intervention was vitamin C only the studies included 226 women with 117 in 
the control groups and 109 in the intervention groups.  Appendix B includes more information on 
the study characteristics, as well as some of the key points used to determine study quality. 
Initial 
Searches 
Duplicates 
Removed 
Title and 
Abstract 
Review 
Full Text 
Review 
PUBMED-121 Results 
Cochrane-103 Results 
EMBASE-105 Results 
99 Duplicates Removed 203 Unique Articles 
198 Excluded 32 Articles Identified for Full Text Review 
23 Excluded: 
6- Systematic reviews 
2- Descriptions of ongoing studies 
4- Secondary analyses of an included 
study 
5- Did not report outcome of interest 
3- Did not use intervention of interest 
3- Did not meet setting criteria 
9 Articles Identified for 
Quality Review 
Figure 1 
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Table 2: Overview Statistics of Studies Included in Quality Assessment 
Vitamin C Only 
Author(s) Publication 
Year 
Study 
Population 
Risk Profile* 
Intervention No. of 
Controls 
No. receiving 
Intervention 
Haji Foghaha, M. et 
al(28) 
2009 Low Vitamin C 100mg/d 60 57 
Casanueva, E. et 
al(29) 
2005 Low Vitamin C 100mg/d 57 52 
Vitamin C and E 
Author(s) Publication 
Year 
Study 
Population 
Risk Profile* 
Intervention No. of 
Controls 
No. receiving 
Intervention 
Xu, H. et al(30) 2010 Low** 
Vitamin C 1000mg/d 
& Vitamin E 400IU/d 
 
1293 1243 
Roberts, J. et al(31) 2010 Low 4976 4993 
Rumbold, A. et 
al(32) 
2006 Low 942 935 
McCance, D. et 
al(33) 
2010 High 374 375 
Poston, L. et al(34) 2006                              High 1376 1372 
Beazley, D. et 
al(35) 
2005 High 48 52 
Chappell, L. C. et 
al(36) 
1999 High 142 141 
* Population risk profile defined as: High=Previous history of obstetrical complications, abnormal uterine artery 
Doppler waveforms or chronic medical condition (e.g. diabetes mellitus or hypertension requiring medication). 
Low=No previous history of obstetrical complications or chronic medical disease. 
** Study included a high and low risk group; however, many of the risk factors mentioned above were excluded 
from both groups and the high risk group was less than 30% of the study population 
Quality of Studies 
 Using the quality criteria laid out in the methods section, we rated each study as good, 
fair, or poor.  The grading of the studies is summarized in Table 3 and described here with 
additional information in Appendix B.  Two studies, one by Haji Foghaha et al(28) and the 
second by Beazley et al(35) could not be appropriately assessed due to a lack of information 
available in their respective articles.  Emails were sent to the contact information provided within 
the articles to request further information; however, no responses were received prior to the 
completion of this review.  In the remaining seven studies, we rated three studies as good quality 
in respect to their internal validity and four graded as fair quality using the grading criteria given 
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in the methods section.  The most common reasons we considered a study fair instead of good 
was either not enough information provided on the presence of risk factors and any differences 
between the intervention and control group or different rates of known risk factors when 
comparing the intervention and control group.  When assessing the external validity, five studies 
were graded as good while two received grades of fair.  One study received a fair grade due to 
differences between the study population and the US population based on demographic and risk 
factor characteristics.  The other study received a fair grade due to its very limited study 
population, patients with type 1 diabetes limiting its generalizability.  For studies dealing with a 
high risk population the external validity was graded based on its generalizability to high risk 
populations in the US and likewise for low risk studies, they were assessed with low risk US 
populations in mind. 
Table 3: Summary of Quality Assessment 
Vitamin C Only 
 Authors Publication 
Year 
Study Population 
Risk Profile 
Internal 
Validity Grade 
External 
Validity Grade 
Haji Foghaha, 
M. et al(28) 
2009 Low N/A N/A 
Casanueva, E. et 
al(29) 
2005 Low Fair Fair 
Vitamin C and E 
 Authors Publication 
Year 
Study Population 
Risk Profile 
Internal 
Validity Grade 
External 
Validity Grade 
Xu, H. et al(30) 2010 Low Fair Good 
Roberts, J. et 
al(31) 
2010 Low Good Good 
Rumbold, A. et 
al(32) 
2006 Low Good Good 
McCance, D. et 
al(33) 
2010 High Fair Fair 
Poston, L. et 
al(34) 
2006                              High Good Good 
Beazley, D. et 
al(35) 
2005 High N/A N/A 
Chappell, L. C. 1999 High Fair Good 
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et al(36) 
Not included in results of this review 
Study Results 
 The individual risk ratios for each study are given in Table 4 below.  When available, this 
data was directly abstracted from the study; however, if necessary the risk ratio and relevant 
confidence interval were calculated using methods described by Armitage and Berry.(37)  For 
studies where the intervention included vitamin C and E the risk ratios ranged from 0.83 to 
1.209. The study by McCance et al(33) reported a statistically significant risk ratio of 0.82 using 
a high risk population.  Specifically, the population used for their study was women with pre-
existing Type 1 diabetes.  However, it should be mentioned here that the rates for history of 
preeclampsia, hypertension, use of antihypertensive medications, and microalbuminuria were 
higher in the placebo group than the intervention group.  Equalizing these risk factors for pre-
term birth, between the two groups would tend to push the risk ratio towards null.  This will be 
discussed further in the section on synthesizing the results of all studies below.  No other studies 
using vitamin C and E as the intervention reported statistically significant risk ratios. 
Only one study where the intervention was vitamin C only was included in the results of 
this review and it reported a risk ratio of 0.548 which was not statistically significant.  The study 
by Casanueva et al(29) used a low risk population in their study. 
Table 4: Summary of Study Outcomes 
Vitamin C Only 
Authors Publication 
Year 
Population 
Risk Profile 
Intervention Risk Ratio 95% Confidence 
Interval 
Haji Foghaha, 
M. et al(28) 
2009 Low Vitamin C 
100mg/d 
¥ ¥ 
Casanueva, E. 
et al(29) 
2005 Low Vitamin C 
100mg/d 
0.5481* (0.2400,1.2516)* 
Vitamin C and E 
Authors Publication Population Intervention Risk Ratio 95% Confidence 
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Year Risk Profile Interval 
Xu, H. et 
al(30) 
2010 Low 
Vitamin C 
1000mg/d 
& 
Vitamin E 
400IU/d 
1.07 (0.89,1.29) 
Roberts, J. et 
al(31) 
2010 Low 0.97 (0.87,1.09) 
Rumbold, A. et 
al(32) 
2006 Low 1.02 (0.73,1.43) 
McCance, D. 
et al(33) 
2010 High 0.83 (0.69,1.00) 
Poston, L. et 
al(34) 
2006                              High 1.07 (0.93,1.22) 
Beazley, D. et 
al(35) 
2005 High 1.319* (0.754,2.306)* 
Chappell, L. C. 
et al(36) 
1999 High 1.209* (0.377,3.869)* 
¥ Unable to calculate from article: Incidence rates in proportions did not correspond to a whole number of 
individuals.  High likelihood a typo is the root cause but the possible correction is not reported here out of caution. 
*Not reported in original article: Calculated from available data. 
Not included in results of this review 
Synthesis of Study Results 
 The next step in this review was to use the information from above describing a studies 
characteristics, quality, and outcomes and synthesize some overall conclusions.  Here I will 
discuss how this information was combined and point out key decisions made during the process 
and an analysis of the use of these results in public health and the clinical setting will follow 
below in the discussion section.  As noted in the methods section above, the evidence level for 
the key question will be assessed for each intervention category and risk level using the USPSTF 
procedure manual as a guide.  Therefore, I will report grades for the level of evidence as 
convincing, adequate, or inadequate.(27) 
Vitamin C – Low Risk 
Only one study was found using vitamin C only that was able to be assessed for quality 
and included in this review.  The study by Casanueva et al(38) studied a low risk population 
which excluded women with medical disease, multiple gestations, and obstetrical indications for 
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a Cesarean section.  In this study there was no statistically significant difference in preterm birth 
rates between the intervention (vitamin C 100mg/d) and the placebo group.  The study included 
only 109 women and reported a minimal number of incidence rates for preterm birth risk factors 
resulting in fair internal validity.  The study had fair external validity partly due to possible 
differences in natural vitamin intake levels and other risk factors between its source population in 
Mexico and the general US population.  The primary outcome of the study was premature 
rupture of membranes which is a likely reason the authors’ did not report the incidence rate of 
previous preterm birth (and other risk factors) in the study population.  Since this is the only 
study with vitamin C only as the intervention in a low risk group, I have graded the level of 
evidence to be inadequate to conclude whether vitamin C use in a low risk population will 
prevent preterm birth.(29) 
Vitamin C – High Risk 
No study was identified using Vitamin C only in a high risk population.  Therefore, the 
evidence level for vitamin C use to prevent preterm labor in high risk women is considered 
inadequate. 
Vitamin C and E – Low Risk 
Three studies included in this review used vitamin C and E in low risk women.  Two 
studies by Roberts et al(31) and Rumbold et al(32) received grades of good for internal and 
external validity, have high study populations n=9,969 and 1,877 respectively, and reported 
outcomes showing no significant differences between the intervention and control group.  The 
third study by Xu et al(30) contained a population with a slightly higher risk profile than other 
studies defined as low risk in this review.  Despite being stopped early due to safety concerns 
and based on conclusions from other studies published during the trial, Xu et al’s article included 
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2,536 participants.  The early cessation of the study and higher rates of multiple gestations in the 
placebo group were factors in our determination to assign an internal validity grade of fair to this 
study.  However, the study had good external validity and contained a population with a wider 
range of risk profiles than other studies in this review.  The outcome of the Xu et al study 
showed no statistically significant difference in preterm birth between the intervention group and 
control group.  The risk ratios for the three studies were slightly below null in Roberts et al 
(RR=0.97) and slightly above null for Xu et al (RR=1.07) and Rumbold et al (RR=1.02).  
Roberts et al’s study population was approximately twice the size as the other two studies 
combined.  Given this data, the conclusion of this review is the level of evidence for vitamin C 
and E use during pregnancy is convincing that there is no effect on preterm birth rates in a low 
risk population.(30-32) 
Vitmain C and E – High Risk 
The remaining three studies in this review assessed the use of vitamin C and E in high 
risk study populations.  Although there are more studies in this category, the total number of 
study participants is less than in the low risk studies: 3,780 high risk study participants versus 
14,382 low risk study participants.  Also, these studies had a higher degree of variability in their 
study population characteristics and internal and external validity.  Only one study by Poston et 
al(34) was assessed to have good internal and external validity and also had the highest number 
of study participants with almost as many as the remaining studies combined.  This study with 
2,748 women possessing at least one obstetrical risk factor, including 21% having more than one 
risk factor, reported a non-statistically significant difference between the intervention group and 
placebo group that was slightly above null (RR=1.07).   
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The remaining two studies were deemed to contribute less to the level of evidence for the 
following reasons: The McCance et al(33) study with 749 women was rated fair partly due to its 
high risk of confounding (higher incidence of prior preeclampsia, hypertension, antihypertensive 
treatment, and microalbuminuria in the placebo group) that would push it’s reported risk ratio of 
0.83 closer to the null.  The study had fair external validity mainly due to its low level of 
generalizability because it used only women with type 1 diabetes.  Finally, Chappell et al’s(36) 
study with 203 women had fair internal validity for a variety of reasons (adherence rates not 
reported, high dropout rate compared to other studies (~20%), and a higher proportion of women 
of African descent in the placebo group) and good external validity.  Chappell et al reported a 
risk ratio of 1.209; however, the confidence interval was very wide due to the low sample size 
(95% CI=0.377-3.869).(33, 36, 39) 
Statistically combining the results of the three studies assessing vitamin C and E in high 
risk women would be a useful tool to help assess the level of evidence; however, it is beyond the 
scope of this review.  Therefore, looking at the three studies and what they say about the 
evidence as an aggregate we considered the following key points: the number of study 
participants giving outcomes below the null (749) and above (3031) were not insignificant nor 
extremely large, all risk ratios approached null especially when accounting for possible 
confounders that would push the risk ratio closer to null in studies(33, 39) with results further 
from it, and the study with the best internal validity(34, 40) produced the results closest to null.  
Based on this information we determined that the level of evidence is adequate that using 
vitamin C and E in high risk pregnant women will not decrease preterm birth rates.(33, 34, 36, 
39, 40) 
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Assessment of Bias Across Studies 
 I searched PUBMED, Web of Science, and EMBASE for conference papers, abstracts, or 
other conference proceedings and found 51 results.  Six of these results matched with one of the 
articles included in the quality assessment of this review.  The remaining 45 results did not 
match the inclusion and exclusion criteria of this review based on the title and abstract data 
available.   
I searched clinicaltrials.gov and found 18 studies matching the search terms.  One of 
these studies matched articles included in this review and 16 of the remaining could be excluded 
from this study based on the information provided on the website.  One study could provide data 
to be included in this review but was not yet completed.  The study, clinicaltrials.gov 
identifier=NCT00632476 is investigating the effects of vitamin C on infant lung health.  
However, it may report data on the number of pre-term births as well and this data could be 
added to the body of evidence.  Targeted searches of PubMed and EMBASE using the principal 
investigators name and dates of the study did not provide any further information on the study’s 
results.  However, since this study was not yet completed, its lack of article results in the 
database searches does not indicate publication bias.   
Based on this information I did not find evidence for a publication bias; however, this is 
not evidence of a lack of publication bias either.  On the other hand, most of the studies included 
in this review had an outcome consistent with a null risk factor and the primary concern with 
publication bias is a lack of these studies being reported.  Therefore the risk of publication bias 
affecting this review is minimal. 
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DISCUSSION 
Summary of Evidence 
 The original focus of this review was to determine the evidence available regarding 
vitamin C supplementation during pregnancy and its effect of the incidence of preterm birth.  
Due to the variety in study populations present in the studies identified during the database 
searches we decided to divide our conclusions into four groups.  The type of intervention the 
study used (vitamin C alone or C and E combined) and the study population risk profile (high or 
low) determined which group a study belonged in.  Here we will discuss how the level of 
evidence available within each group can be used to direct health care. 
Vitamin C – Low Risk 
 There was only one study identified that studied a low risk population with vitamin C 
alone as the intervention done by Casanueva et al.(38)  The study produced a risk ratio with a 
wide confidence interval including the possibility of no effect; therefore the level of evidence for 
vitamin C in low risk women was considered inadequate.  From a public health perspective, this 
level of evidence cannot be used to drive policy on the population level.  Likewise given this 
level of evidence, this review cannot make any recommendations to be utilized by the clinician 
during individual patient encounters.  The vitamin C dose was lower for this study than many of 
the other at 100mg/day.  With this dose, no harms were identified during the study.  However, 
detection of harms was not the target of the study and typically requires a larger study population 
than what the study obtained with 109 women participating.  Therefore, while this study does not 
provide evidence for the use a vitamin C during pregnancy for prevention of preterm birth, it also 
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does not provide evidence against the continued use of multivitamin supplements containing 
vitamin C. 
Vitamin C – High Risk 
 No study was identified with vitamin C alone as the intervention in a high risk 
population. Therefore, we are unable to make any recommendations on a population level to 
assist public health professionals or to aid in clinical decision making. 
Vitamin C and E – Low Risk 
 The group of three studies using vitamin C and E in a low risk population were all well 
done and taken together produce convincing evidence that there is no effect of the rate of preterm 
birth with vitamin C 1000mg/day and vitamin E 400IU/day.  For public health policy, this 
evidence argues against implementing this intervention in any widespread fashion.  I would point 
out here that the evidence does not suggest the current recommendations for multivitamin use 
during pregnancy should be changed.  These studies investigated a relatively high dose of 
vitamin C and E supplementation targeting the prevention of specific outcomes whereas 
multivitamin supplementation is an effective means to maintain adequate intake on a population 
level where the dietary intake varies greatly within the general population.  For individual 
patients, the evidence is enough evidence showing a lack of benefit that a clinician should only 
recommend this treatment if the patient has a known deficiency of vitamin C or E or some other 
indication for the intervention.  The studies did not provide any evidence of increased harms 
from the intervention with relatively high total number of study participants. 
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Vitamin C and E – High Risk 
 There were three studies using high risk populations with vitamin C and E as the 
intervention.  From these studies I concluded the level of evidence was adequate to say vitamin 
C and E use during pregnancy for high risk groups would not reduce the rate of preterm birth.  
Analogous to above for low risk groups, the evidence indicates there should not be a population 
wide recommendation to use vitamin C and E for prevention of preterm birth in high risk 
women.  Also, as above, the evidence does not support the widespread use of vitamin C and E in 
the clinical setting to prevent preterm birth.  However, if there is reason for a clinician to believe 
their patient has a specific need for vitamin C and E supplementation for other reasons, it may be 
useful for reasons other than prevention of preterm birth.  Therefore, clinicians can make a 
judgment based on the patient if there is a perceived benefit other than what is covered by these 
studies. 
Harms 
None of the studies included in this review reported outcomes related to the typical side 
effects of vitamin C toxicity: diarrhea or other gastrointestinal disturbances.  Xu et al(30) 
reported an increase risk of fetal loss or perinatal death and preterm premature rupture of 
membranes in their intervention group.  Roberts et al(31),Rumbold et al(32), and Poston et al(34) 
found an increased risk of gestational hypertension and the need for antihypertensive therapy 
within their intervention groups.  Poston et al also found higher rates of small and growth 
restricted singleton babies born to women with diabetes taking vitamin C and E in some of their 
sub-group analyses.  These harms provide more evidence against the widespread use of vitamin 
C to prevent preterm birth, especially without evidence of benefit. 
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Limitations of the Available Studies 
 One limitation of this review due to the studies included is because most studies had a 
primary outcome different than this review’s outcome of interest which is preterm birth.  When 
performing a trial, investigators invariably dedicate more effort to enhancing the study with 
respect to their primary outcome.  The study is designed to provide the best data to analyze the 
link between the intervention and primary outcome by implementing better control for 
confounders, maintaining valid measurements, obtaining adequate sample sizes, etc.  This also 
becomes a limitation in terms of the information provided in the article available to reviewers.  
We could not assess the comparability between the intervention and placebo groups on some risk 
factors because they were not reported in the articles available.  Risk factors that would not 
affect the primary outcome are typically not reported even though they may have a large effect 
on our review’s outcome.  Most studies included adequate randomization techniques which 
would limit any differences between the intervention and placebo group.  We can assume the 
randomization would produce comparable groups.  Therefore the limitation is the need for an 
assumption rather and not necessarily that the groups were not comparable. 
 One other limitation common in many of the studies included in this review was lack of 
any data obtained or at least not reported in the article on the background vitamin C intake of the 
study participants.  Some of the studies used food surveys and other methods to derive some 
information on the level of vitamin C consumption in their participants.  These methods have 
their own associated inaccuracies but they provided more data than the studies that did not report 
any information on this subject.  Without this information we cannot make conclusions on 
whether there is a threshold intake level that would demonstrate some benefit in patients with 
poor nutritional statuses.  Some of the studies focused on populations where poor nutrition was 
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more relevant; however, since we do not know how the intake levels in their populations 
compare to those in the studies in populations with better nutrition.  Similarly although most 
studies had exclusion criteria related to intake of vitamin supplements containing vitamin C, the 
level of intake used varied among the studies and as above it would be difficult to know what 
amount of vitamin C intake would be confounding.  Therefore, this can also be seen as a 
limitation of the available studies used in this review.  The specific exclusion criteria are listed in 
Appendix B. 
 No study was identified in our search that used vitamin C alone in a high risk population.  
Without any evidence for this population we were unable to make conclusions regarding the 
benefit or harm of the intervention. 
 Vitamin C toxicity is typically associated with diarrhea and other gastrointestinal 
disturbances when high doses >3grams per day are ingested.  None of the studies used doses at 
this level or had populations large enough to have sufficient power to further investigate this 
harm.  However, some negative differences between intervention and control groups were 
identified by the studies as mentioned above. 
 Another limitation of this review is related to the difference in preterm delivery due to 
spontaneous labor versus medically indicated iatrogenic causes of preterm birth.  As mentioned 
in the introduction around 20% of all preterm births are secondary to other obstetrical 
complications.  Most of the articles used in this review did not report data on the preterm birth 
rate separately for spontaneous labor versus other causes.  Therefore, within the scope of this 
review I cannot draw any conclusions on the vitamin C’s effect on the different causes of 
preterm birth. 
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Limitations of Our Review 
 One of the primary concerns of any systematic review is publication bias affecting the 
conclusions.  Typically, publication bias would tend to push any outcome measure away from 
null and artificially enhance the benefits of the intervention.  In general, it is impossible to prove 
that a bias is not present.  I attempted as part of the review to look for evidence of publication 
bias to help determine the probability it is affecting our conclusions.  I searched clinicaltrials.gov 
to look for registered studies that were completed but without available results.  I talked to an 
expert in the field to found out if they could identify trials not included in the studies identified 
by my database search.  I also searched multiple databases for conference abstracts and similar 
pieces of information about studies done that may not have been published as journal articles 
captured by my search.  After performing all of the above, I did not find any trials that fit this 
review which would support a low probability of publication bias affecting my results.  
However, I cannot eliminate the possibility completely and this should always be taken into 
account as a limitation of the review. 
 Another limitation of this review was the requirement that any individual study have 
information published in English to allow for the reviewers to assess the study and abstract the 
relevant data necessary for the review.  This limitation is mitigated somewhat since most trials 
with study populations similar to the general US population are often published in English as 
well as any native languages.  However, they are many trials that are not published in English.  
This limitation can combine with publication bias by limiting the data of important trials 
performed in other languages that are not deemed ‘important’ enough to be translated for 
publication in English. 
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 A limitation of every review is the possibility of missing trials published and present in 
the databases searched but missed by the reviewers due to a poor search strategy.  A research 
librarian was consulted in developing the overall search strategy for this review.  However, due 
to resource constraints the search needed to be focused some which may have excluded studies 
that would have contributed to this review.  In particular, MEDLINE categories were utilized in 
the primary PUBMED search and filters were also used in the EMBASE search.  Using these 
filters and MEDLINE indexing can exclude trials that may provide more evidence for this 
review.  I did perform the search to find PUBMED results which were not yet indexed with 
MEDLINE to control for part of this limitation. 
 We excluded two studies identified from the database searches from the results of this 
review due to the lack of information present in the published article to properly assess the trials’ 
validity.  I attempted to obtain more information from the authors of each of these studies but did 
not receive anything before the conclusion of this review.  The results of these two studies as 
reported in the articles we obtained were similar to those in the studies that were included in this 
review.  Therefore, the conclusions drawn would not have changed dramatically.  These two 
studies are examples of a limitation of reviews since they are only based on the information on 
each study that is provided to them by the authors.  Additional information on any given trial 
may have affected the assessment of its internal or external validity as well as its inclusion in the 
review.  Contacting the authors of the two identified studies was an attempt to mitigate this 
limitation but it is still present for these articles as well as all the articles included in the review. 
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CONCLUSIONS 
 Using vitamin C alone to prevent preterm birth was only addressed in one study 
identified by this review.  The study had fair validity.  Therefore, the level of evidence is 
inadequate to make any recommendations related to public health policy or clinical decision 
making.  There were six studies on vitamin C and E which produce a high level of evidence 
showing no beneficial effect of the intervention on preterm birth rates.  In addition, there was 
some evidence in the studies of increased harms in the intervention groups which means the 
harms may outweigh any unproven benefits related to preterm birth. 
 Typically the lack of studies on vitamin C alone combined with the biochemical evidence 
suggesting a benefit would encourage further research in this area.  However, the biochemical 
evidence is based on the antioxidant properties of vitamin C.  Therefore, studies using vitamin C 
and E, both antioxidants should also have showed a benefit based on the biochemical data.  
However, eight studies on vitamin C and E in this review provided a high level of evidence of no 
benefit.  If an effect had been seen with vitamin C and E, but not observed in the two vitamin C 
only studies, they would be a stronger impetus to perform more vitamin C only studies.  This 
would help determine if the effect was due to vitamin C but not observed in the small studies 
performed thus far for some reason or due to vitamin E.  However, since there did not appear to 
be an improvement even when using two antioxidants, there is less of an impetus to differentiate 
the effects of vitamin C and E based on the biochemical evidence alone.  
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APPENDIX A – SEARCH STRATEGY 
 The following searches were performed: 
1. PUBMED- ((ascorbic acid) OR (vitamin C)) AND (pregnant OR pregnancy) with 
limitations of: Human AND (Meta Analysis OR Randomized Controlled Trial) AND 
English 
2. PUBMED- ((ascorbic acid) OR (vitamin C)) AND (pregnant OR pregnancy) without 
MEDLINE indexing 
3. EMBASE- 'ascorbic acid' OR 'vitamin c' AND (pregnant OR pregnancy) AND 
[humans]/lim AND [english]/lim filtered to include only randomized controlled trials’ 
4. Cochrane- ((ascorbic acid) OR ("vitamin C")) AND (pregnant OR pregnancy) :ti,ab,kw 
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APPENDIX B – QUALITY ASSESSMENT AND STUDY POPULATION SUMMARY 
 The tables below summarize some of the pertinent points found when assessing the 
quality of each study.  The groups mentioned in the tables are the intervention and placebo 
group.  Only information pertinent to the outcome of interest for this review is discussed below.  
Also some details are not written below if they are not informative to the assessment process.  
For instance, having similar age ranges in the groups or average parity are not reported as risk 
factors consistent between the groups but would be pointed out if they are inconsistent.  Another 
example is that all studies provided results for the outcome of preterm birth that could be 
considered intention to treat and this review did not use any adjusted rates; therefore, a 
discussion of the analytical methods of the studies is not included. 
Casanueva et al, 2005(38) 
Source Population Prenatal patients at one clinic in Mexico City 
Inclusion Criteria No acute or chronic diseases, singleton pregnancy, no vitamin use 
Exclusion Criteria Uterine cerclage, indication for cesarean delivery 
Risk Factors Consistent 
Between Groups 
Nutritional status, socioeconomic status, smoking rates.  Overall a 
low number of factors reported. 
Risk Factors Inconsistent 
Between Groups 
None reported 
Dropout, Adherence <10% dropout, >80% adherence 
Randomization, Blinding Randomized by principal investigator, study personnel and 
participants blinded 
Other Potential 
Confounders 
 
Adherence measurement by self-report of participants 
Other Comments Food-diet questionnaires performed to assess dietary intake of 
vitamin C 
Internal Validity Grade Fair 
External Validity Grade Fair 
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Xu et al, 2010(30) 
Source Population Multiple centers in Canada and Mexico 
Inclusion Criteria  
Exclusion Criteria Warfarin use, fetal abnormalities, history of medical complications, 
repeated abortions, illicit drug use. >200mg/d vitamin C and/or 
50IU/d vitamin E intake from other sources 
Risk Factors Consistent 
Between Groups 
Previous use of vitamin supplements, family and obstetrical histories 
Risk Factors Inconsistent 
Between Groups 
More multiple gestations in placebo group 
Dropout, Adherence Dropout rate= ~10%, adherence equal among groups (~85%) 
Randomization, Blinding Adequate 
Other Potential 
Confounders 
 
Other Comments Important confounders reported, study stopped early, mix of low and 
moderate risk patients 
Internal Validity Grade Fair 
External Validity Grade Good 
 
Roberts et al, 2010(31) 
Source Population 16 clinical centers in the US 
Inclusion Criteria Singleton, nulliparous gestations 
Exclusion Criteria Systolic blood pressure>135, diastolic blood pressure>85, 
proteinuria, current or past use of antihypertensive medication, 
history of diabetes prior to pregnancy, treatment with antiplatelet 
drugs, Non-steroidal anti-inflammatory drugs, recent uterine 
bleeding, serious medical conditions, fetal anomaly, in vitro 
fertilization, illicit drug or alcohol abuse. >150mg/d of vitamin C or 
75IU/d vitamin E intake from other sources. 
Risk Factors Consistent 
Between Groups 
Race, smoking status, educational level, family history 
Risk Factors Inconsistent 
Between Groups 
None reported  
Dropout, Adherence Adherence=88% in both groups, low dropout rate (1.8%) 
Randomization, Blinding Adequate 
Other Potential 
Confounders 
77% of participants reported taking a vitamin supplement at study 
entry 
Other Comments Study had a run-in period, extremely low risk group 
Internal Validity Grade Good 
External Validity Grade Good 
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Rumbold et al, 2006(32) 
Source Population Multiple centers in New Zealand and Australia 
Inclusion Criteria Singleton, nulliparous gestations, normal blood pressure at first two 
measurements of study 
Exclusion Criteria Fetal anomaly, thrombophillia, chronic renal failure, 
antihypertensive therapy. No multivitamin use containing more than 
200mg/d of vitamin C or 50IU/d of vitamin E. 
Risk Factors Consistent 
Between Groups 
History of prior abortion, race, education level, adequate dietary 
intake of vitamin C and E 
Risk Factors Inconsistent 
Between Groups 
None reported 
Dropout, Adherence Dropout: all participants had birth data reported, adherence equal 
between groups 
Randomization, Blinding Adequate 
Other Potential 
Confounders 
 
Other Comments  
Internal Validity Grade Good 
External Validity Grade Good 
 
McCance et al, 2010(33) 
Source Population Antenatal metabolic clinics in Northern Ireland, Scotland, northwest 
England 
Inclusion Criteria Type 1 diabetes, singleton gestation 
Exclusion Criteria Warfarin treatment, drug use. Multivitamins could not contain more 
than 50mg/d of vitamin C or 200IU/d of vitamin E. 
Risk Factors Consistent 
Between Groups 
HgbA1C, insulin dose, smoking status, multivitamin use 
Risk Factors Inconsistent 
Between Groups 
History of preeclampsia, hypertension, antihypertensive treatment, 
microalbuminuria more common in placebo group 
Dropout, Adherence Dropout=1 participant,  
Randomization, Blinding Adequate 
Other Potential 
Confounders 
 
Other Comments Limited generalizability given specific study population with type 1 
diabetes 
Internal Validity Grade Fair 
External Validity Grade Fair 
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Poston et al, 2006(34) 
Source Population Referrals from entire UK possible, 13 participants from Holland 
Inclusion Criteria Preeclampsia in preceding pregnancy or preterm delivery or HELLP 
or eclampsia or antihypertensive therapy, or diastolic blood pressure 
>90mm Hg prior to 20weeks gestational age, type 1 or 2 diabetes 
requiring therapy, antiphospholipid syndrome, chronic renal disease, 
multiple gestation, abnormal uterine artery Doppler, primiparous 
with BMI>30kg/m2 
Exclusion Criteria Warfarin treatment. Taking supplement with >200mg/d vitamin C or 
40IU/d vitamin E. 
Risk Factors Consistent 
Between Groups 
Education, smoking status, multivitamin use, risk factors in 
inclusion criterion 
Risk Factors Inconsistent 
Between Groups 
None reported 
Dropout, Adherence Dropout=0.4%, Adherence equal between groups 
Randomization, Blinding Adequate 
Other Potential 
Confounders 
 
Other Comments  
Internal Validity Grade Good 
External Validity Grade Good 
 
Chappell et al, 1999(36) 
Source Population One hospital clinic and one high risk antennal clinic at a second 
hospital in the UK 
Inclusion Criteria Abnormal Doppler waveform or history in preceeding pregnancy of 
preeclampsia needing preterm delivery, eclampsia or HELLP 
Exclusion Criteria Warfarin or heparin treatment, fetal anomaly, multiple gestation 
Risk Factors Consistent 
Between Groups 
Smoking status, blood pressure, coexisting disease, Doppler analysis 
Risk Factors Inconsistent 
Between Groups 
African heritage 
Dropout, Adherence Dropout=44-25% depending on how initial group is determined, 
adherence not reported 
Randomization, Blinding Adequate 
Other Potential 
Confounders 
 
Other Comments  
Internal Validity Grade Fair 
External Validity Grade Good 
  
[43] 
 
APPENDIX C – PRETERM BIRTH RISK FACTORS(41) 
• No partner 
• Low socioeconomic status 
• Anxiety 
• Depression 
• Life events (divorce, separation, death) 
• Abdominal surgery during pregnancy 
• Occupational issues (upright posture, use of industrial machines, physical exertion, 
mental or environmental stress related to work or working conditions) 
• Multiple gestation 
• Polyhydramnios 
• Uterine anomaly 
• Uterine leiomyoma 
• Diethylstilbestrol-induced changes in uterus 
• History of second trimester abortion 
• History of cervical surgery 
• Premature cervical dilatation or effacement (short cervical length) 
• Sexually transmitted infections 
• Pyelonephritis, appendicitis, pneumonia 
• Systemic infection 
• Bacteriuria 
• Periodontal disease 
• Placenta previa 
• Placental abruption 
• Vaginal bleeding, especially in more than one trimester 
• Previous preterm delivery 
• Substance abuse 
• Smoking 
• Maternal age (<18 or >40) 
• African-American race 
• Poor nutrition and low body mass index 
• Inadequate prenatal care 
• Anemia (hemoglobin <10 g/dL) 
• Excessive uterine contractility 
• Low level of educational achievement 
• Genotype 
• Fetal anomaly 
• Fetal growth restriction 
• Environmental factors (eg, heat, air pollution) 
  
[44] 
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